Loading...

Nachrichtenliste

Roche T + A immunotherapy research achieves historic breakthrough

2019-12-12


Roche T + A immunotherapy research achieves historic breakthrough

November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical trial aimed at treating liver cancer with Tecentriq (atelizumab) and Avastin (bevacizumab) combination therapy officially. The data shows that in patients with unresectable hepatocellular carcinoma (HCC) who have not previously received systemic treatment, Tecentriq and Avastin immunotherapy group patients achieved significant statistical and clinically significant improvements in overall survival (OS) and progression-free survival (PFS). IMbrave150 is a global phase III, multicenter, open-label study of 501 patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.


Wir möchten Cookies verwenden, um Ihre Nutzung dieser Website besser zu verstehen und Ihre Erfahrung bei zukünftigen Besuchen der Website zu verbessern. Sie können diese Einstellung in Ihren Browsereinstellungen ändern. Weitere Informationen zur Verwendung von Cookies finden Sie in unserer Datenschutzrichtlinie.